Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts

Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody approved in more than 50 countries. Within the European Union, alemtuzumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features; in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Thomas, Elovaara, Irina, Fredrikson, Sten, McGuigan, Chris, Moiola, Lucia, Myhr, Kjell-Morten, Oreja-Guevara, Celia, Stoliarov, Igor, Zettl, Uwe K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Therapy in Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225231/
https://www.ncbi.nlm.nih.gov/pubmed/27882532
http://dx.doi.org/10.1007/s40263-016-0394-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225231/
https://www.ncbi.nlm.nih.gov/pubmed/27882532
http://dx.doi.org/10.1007/s40263-016-0394-8

Ejemplares similares